Titre :

Challenges in Antibody Development against Tn and Sialyl-Tn Antigens

Auteur(s) :

Loureiro, Liliana [Auteur]
Centro de Estudos de Doenças Crónicas [CEDOC]
Universidade Nova de Lisboa = NOVA University Lisbon [NOVA]
Instituto de Biologia Experimental e Tecnológica [IBET]
Carrascal, Mylène [Auteur]
Centro de Estudos de Doenças Crónicas [CEDOC]
Barbas, Ana [Auteur]
Instituto de Biologia Experimental e Tecnológica [IBET]
Ramalho, José [Auteur]
Centro de Estudos de Doenças Crónicas [CEDOC]
Novo, Carlos [Auteur]
Centro de Estudos de Doenças Crónicas [CEDOC]
Universidade Nova de Lisboa = NOVA University Lisbon [NOVA]
Delannoy, Philippe [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Videira, Paula [Auteur]
Centro de Estudos de Doenças Crónicas [CEDOC]
Centro de Recursos Microbiológicos (CREM), Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia

Titre de la revue :

Biomolecules

Numéro :

5

Pagination :

1783-1809

Date de publication :

2015-08-11

ISSN :

2218-273X

Mot(s)-clé(s) en anglais :

Tn antigen
Sialyl Tn antigen
immune response
therapeutic antibodies
antibody production

Discipline(s) HAL :

Chimie/Chimie théorique et/ou physique

Résumé en anglais : [en]

The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with ...
Lire la suite >The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with immunosuppressive microenvironment. Presently they are used in clinical trials as therapeutic vaccination, but with limited success due to their low immunogenicity. Alternatively, anti-Tn and/or STn antibodies may be used to harness the immune system against tumor cells. Whilst the development of antibodies against these antigens had a boost two decades ago for diagnostic use, so far no such antibody entered into clinical trials. Possible limitations are the low specificity and efficiency of existing antibodies and that novel antibodies are still necessary. The vast array of methodologies available today will allow rapid antibody development and novel formats. Following the advent of hybridoma technology, the immortalization of human B cells became a methodology to obtain human monoclonal antibodies with better specificity. Advances in molecular biology including phage display technology for high throughput screening, transgenic mice and more recently molecularly engineered antibodies enhanced the field of antibody production. The development of novel antibodies against Tn and STn taking advantage of innovative technologies and engineering techniques may result in innovative therapeutic antibodies for cancer treatment.Lire moins >

Langue :

Anglais

Audience :

Non spécifiée

Établissement(s) :

CNRS
Université de Lille

Collections :

• Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576

Équipe(s) de recherche :

Régulation de la glycosylation terminale

Date de dépôt :

2020-02-12T15:44:42Z
2021-03-05T11:49:40Z